3 results
The aim of this study is the efficacy of a simplified triple regimen at an energy setting of 12 J/cm2 instead of 2x2x15 J/cm2, without a cleaning phase in between, and its effect on the rate of stenosis and overall complications when using the Barrx…
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72 hours and &…
Primary objective:* To compare the rates of complete recovery (alive, free of dialysis and return of serum creatinine to <150% of reference baseline; equivalent to acute kidney disease (AKD) category 0) at Day 14 between the Reltecimod-…